

Iwei Yeh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4282797/publications.pdf>

Version: 2024-02-01

89
papers

5,650
citations

87888

38
h-index

82547

72
g-index

124
all docs

124
docs citations

124
times ranked

7943
citing authors

#	ARTICLE	IF	CITATIONS
1	The Genetic Evolution of Melanoma from Precursor Lesions. <i>New England Journal of Medicine</i> , 2015, 373, 1926-1936.	27.0	824
2	Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. <i>Nature Communications</i> , 2014, 5, 3116.	12.8	521
3	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. <i>Nature Genetics</i> , 2015, 47, 1194-1199.	21.4	221
4	UVB radiation generates sunburn pain and affects skin by activating epidermal TRPV4 ion channels and triggering endothelin-1 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E3225-34.	7.1	208
5	Computational Analysis of Plasmodium falciparum Metabolism: Organizing Genomic Information to Facilitate Drug Discovery. <i>Genome Research</i> , 2004, 14, 917-924.	5.5	206
6	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. <i>Nature Communications</i> , 2019, 10, 3163.	12.8	205
7	Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution. <i>Cancer Cell</i> , 2018, 34, 45-55.e4.	16.8	157
8	Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. <i>Neuro-Oncology</i> , 2017, 19, now254.	1.2	155
9	Activating MET kinase rearrangements in melanoma and Spitz tumours. <i>Nature Communications</i> , 2015, 6, 7174.	12.8	139
10	Clinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions. <i>American Journal of Surgical Pathology</i> , 2015, 39, 581-591.	3.7	129
11	<sc>NTRK3</sc> kinase fusions in Spitz tumours. <i>Journal of Pathology</i> , 2016, 240, 282-290.	4.5	128
12	Human tumor genomics and zebrafish modeling identify <i>SPRED1</i> loss as a driver of mucosal melanoma. <i>Science</i> , 2018, 362, 1055-1060.	12.6	123
13	Targeted Genomic Profiling of Acral Melanoma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1068-1077.	6.3	118
14	Recurrent <sc>BRAF</sc> kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 845-851.	3.3	114
15	Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. <i>Cancer Cell</i> , 2018, 34, 56-68.e9.	16.8	113
16	Combined activation of MAP kinase pathway and β -catenin signaling cause deep penetrating nevi. <i>Nature Communications</i> , 2017, 8, 644.	12.8	107
17	Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. <i>Nature Communications</i> , 2019, 10, 353.	12.8	99
18	Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. <i>Modern Pathology</i> , 2017, 30, 246-254.	5.5	95

#	ARTICLE	IF	CITATIONS
19	Clonal BRAF Mutations in Melanocytic Nevi and Initiating Role of BRAF in Melanocytic Neoplasia. <i>Journal of the National Cancer Institute</i> , 2013, 105, 917-919.	6.3	92
20	Melanoma models for the next generation of therapies. <i>Cancer Cell</i> , 2021, 39, 610-631.	16.8	90
21	Knowledge acquisition, consistency checking and concurrency control for Gene Ontology (GO). <i>Bioinformatics</i> , 2003, 19, 241-248.	4.1	81
22	The genomic landscapes of individual melanocytes from human skin. <i>Nature</i> , 2020, 586, 600-605.	27.8	79
23	Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF- κ B pathway activation. <i>Modern Pathology</i> , 2018, 31, 660-673.	5.5	76
24	Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. <i>Modern Pathology</i> , 2019, 32, 88-99.	5.5	76
25	Ambiguous Melanocytic Tumors With Loss of 3p21. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1088-1095.	3.7	75
26	Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 607-610.	3.3	70
27	Spitz melanoma is a distinct subset of spitzoid melanoma. <i>Modern Pathology</i> , 2020, 33, 1122-1134.	5.5	67
28	Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 439-449.	7.0	64
29	Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. <i>Modern Pathology</i> , 2017, 30, 1086-1099.	5.5	63
30	Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. <i>Cell Reports</i> , 2019, 29, 573-588.e7.	6.4	62
31	The genetic landscape of gliomas arising after therapeutic radiation. <i>Acta Neuropathologica</i> , 2019, 137, 139-150.	7.7	57
32	A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. <i>Nature Communications</i> , 2018, 9, 810.	12.8	56
33	Filigree-like Rete Ridges, Lobulated Nests, Rosette-like Structures, and Exaggerated Maturation Characterize Spitz Tumors With NTRK1 Fusion. <i>American Journal of Surgical Pathology</i> , 2019, 43, 737-746.	3.7	55
34	Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. <i>Modern Pathology</i> , 2016, 29, 1012-1027.	5.5	54
35	Diffuse Infantile Hepatic Hemangiomas: A Report of Four Cases Successfully Managed with Medical Therapy. <i>Pediatric Dermatology</i> , 2011, 28, 267-275.	0.9	50
36	Distinguishing neurofibroma from desmoplastic melanoma: the value of the CD34 fingerprint. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 625-630.	1.3	47

#	ARTICLE	IF	CITATIONS
37	Melanoma Arising in a Large Plaque-type Blue Nevus With Subcutaneous Cellular Nodules. American Journal of Surgical Pathology, 2012, 36, 1258-1263.	3.7	41
38	Prognostic factors and survival in acral lentiginous melanoma. British Journal of Dermatology, 2017, 177, 428-435.	1.5	41
39	Melanocytic tumors with MAP3K8 fusions: report of 33 cases with morphological-genetic correlations. Modern Pathology, 2020, 33, 846-857.	5.5	38
40	Differential expression of PHLDA1 (TDAG51) in basal cell carcinoma and trichoepithelioma. British Journal of Dermatology, 2012, 167, 1106-1110.	1.5	37
41	Melanoma <i>ex</i> blue nevus: two cases resembling large plaque-type blue nevus with subcutaneous cellular nodules. Journal of Cutaneous Pathology, 2012, 39, 1094-1099.	1.3	37
42	Cutaneous Non-Neural Granular Cell Tumors Harbor Recurrent ALK Gene Fusions. American Journal of Surgical Pathology, 2018, 42, 1133-1142.	3.7	33
43	MicroRNA Ratios Distinguish Melanomas from Nevi. Journal of Investigative Dermatology, 2020, 140, 164-173.e7.	0.7	32
44	Genomic and Clinicopathologic Characteristics of PRKAR1A-inactivated Melanomas. American Journal of Surgical Pathology, 2020, 44, 805-816.	3.7	31
45	SOX10 expression in cutaneous myoepitheliomas and mixed tumors. Journal of Cutaneous Pathology, 2014, 41, 353-363.	1.3	30
46	Cutaneous Mycobacterial Spindle Cell Pseudotumor: A Potential Mimic of Soft Tissue Neoplasms. American Journal of Dermatopathology, 2011, 33, e66-e69.	0.6	29
47	New and evolving concepts of melanocytic nevi and melanocytomas. Modern Pathology, 2020, 33, 1-14.	5.5	28
48	Melanoma pathology: new approaches and classification*. British Journal of Dermatology, 2021, 185, 282-293.	1.5	25
49	Drug Targets for Plasmodium falciparum: A Post-Genomic Review/Survey. Mini-Reviews in Medicinal Chemistry, 2006, 6, 177-202.	2.4	24
50	Inactivating <i>MUTYH</i> germline mutations in pediatric patients with high-grade midline gliomas. Neuro-Oncology, 2016, 18, 752-753.	1.2	20
51	Fusion partners of NTRK3 affect subcellular localization of the fusion kinase and cytomorphology of melanocytes. Modern Pathology, 2021, 34, 735-747.	5.5	20
52	Evaluation and management of a patient with chronic pruritus. Journal of Allergy and Clinical Immunology, 2012, 130, 1015-1016.e7.	2.9	19
53	Molecular Melanoma Diagnosis Update. Clinics in Laboratory Medicine, 2017, 37, 473-484.	1.4	18
54	Plexiform melanocytic schwannoma: a mimic of melanoma. Journal of Cutaneous Pathology, 2012, 39, 521-525.	1.3	17

#	ARTICLE	IF	CITATIONS
55	Ultraviolet light-related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site. <i>Head and Neck</i> , 2019, 41, E82-E85.	2.0	17
56	GNAQ ^{Q209L} expression initiated in multipotent neural crest cells drives aggressive melanoma of the central nervous system. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 96-111.	3.3	16
57	Detection of cryptogenic malignancies from metagenomic whole genome sequencing of body fluids. <i>Genome Medicine</i> , 2021, 13, 98.	8.2	16
58	Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1597-1605.	3.7	16
59	Spitz melanocytic tumours—a review. <i>Histopathology</i> , 2022, 80, 122-134.	2.9	16
60	Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	15
61	An infiltrative variant of non-neural granular cell tumor: a case report. <i>Journal of Cutaneous Pathology</i> , 2009, 36, 46-51.	1.3	14
62	Eruptive Spitz nevus, a striking example of benign metastasis. <i>Scientific Reports</i> , 2020, 10, 16216.	3.3	13
63	Expanding the Spectrum of Microscopic and Cytogenetic Findings Associated With Spitz Tumors With 11p Gains. <i>American Journal of Surgical Pathology</i> , 2021, 45, 277-285.	3.7	13
64	Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes. <i>Genome Medicine</i> , 2022, 14, .	8.2	13
65	Neurofibroma-Like Spindle Cell Melanoma. <i>American Journal of Dermatopathology</i> , 2012, 34, 668-670.	0.6	12
66	Topical timolol: An effective treatment option for agminated pyogenic granuloma. <i>Pediatric Dermatology</i> , 2018, 35, e300-e303.	0.9	9
67	Melanotic Schwannoma of the Vulva: A Case Report and Review of the Literature. <i>American Journal of Dermatopathology</i> , 2020, 42, 46-51.	0.6	9
68	Multiple desmoplastic Spitz nevi with BRAF fusions in a patient with ring chromosome 7 syndrome. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 987-993.	3.3	9
69	Evaluation of Crizotinib Treatment in a Patient With Unresectable GPC-RS1 Fusion Agminated Spitz Nevus. <i>JAMA Dermatology</i> , 2021, 157, 836-841.	4.1	9
70	Melanoma BRAF Fusions—Letter. <i>Clinical Cancer Research</i> , 2014, 20, 6631-6631.	7.0	8
71	Eccrine hidradenitis sine neutrophils: a toxic response to chemotherapy. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 905-910.	1.3	7
72	PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 778-783.	4.9	6

#	ARTICLE	IF	CITATIONS
73	Fingerprint CD34 Immunopositivity. <i>Journal of Cutaneous Pathology</i> , 2010, 37, 1127-1127.	1.3	5
74	Supraorbital Cutaneous Fetal Rhabdomyoma of Intermediate Type. <i>American Journal of Dermatopathology</i> , 2014, 36, e93-e96.	0.6	5
75	Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatment. <i>F1000Research</i> , 2016, 5, 1529.	1.6	4
76	Update on classification of melanocytic tumors and the role of immunohistochemistry and molecular techniques. <i>Seminars in Diagnostic Pathology</i> , 2022, 39, 248-256.	1.5	4
77	Chronic <i>Helicobacter cinaedi</i> cellulitis diagnosed by microbial polymerase chain reaction. <i>JAAD Case Reports</i> , 2017, 3, 398-400.	0.8	3
78	Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?. <i>Cancer Genetics</i> , 2017, 216-217, 74-78.	0.4	3
79	Fingerprint CD34 Immunopositivity. <i>Journal of Cutaneous Pathology</i> , 2010, 37, 1128-1129.	1.3	2
80	Madura Foot Caused by <i>Actinomyces madurae</i> in a Pregnant Woman. <i>Archives of Dermatology</i> , 2010, 146, 1189-90.	1.4	2
81	Eosinophilic Pustular Folliculitis in Children after Stem Cell Transplantation: An Eruption Distinct from Graft-versus-Host Disease. <i>Pediatric Dermatology</i> , 2017, 34, 326-330.	0.9	2
82	Response To: Feasibility of a Tumor Progression Model in PRKAR1A-inactivated Melanomas. <i>American Journal of Surgical Pathology</i> , 2021, 45, 869-870.	3.7	1
83	Hypomelanotic Blue Nevi Lack Fingerprint CD34 Immunopositivity. <i>American Journal of Dermatopathology</i> , 2012, 34, 342-343.	0.6	0
84	TB-02UPFRONT, REAL-TIME TUMOR AND GERMLINE SEQUENCING OF PEDIATRIC BRAIN TUMOR PATIENTS: THE UCSF EXPERIENCE. <i>Neuro-Oncology</i> , 2016, 18, iii169.2-iii169.	1.2	0
85	Spitz Tumors. , 2019, , 395-410.		0
86	Deep Penetrating Nevi. , 2019, , 80-89.		0
87	Primary Cilia Are Preserved in Cellular Blue and Atypical Blue Nevi and Lost in Blue Nevus-like Melanoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1205-1212.	3.7	0
88	Spitz Tumors. , 2018, , 1-16.		0
89	A rare case of axillary keratoacanthoma arising in hidradenitis suppurativa. <i>JAAD Case Reports</i> , 2022, 21, 49-51.	0.8	0